Jinling Song; Zhongwu Li; Puyun Chen; Jiangyuan Yu; Feng Wang; Zhi Yang; Xuejuan Wang

doi:10.21147/j.issn.1000-9604.2019.04.07

Chin J Cancer Res> 2019, Vol. 31> Issue(4) : 632-640

Citation: Song J, Li Z, Chen P, Yu J, Wang F, Yang Z, Wang X. A ¹⁸FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer. Chin J Cancer Res 2019;31(4):632-640. doi: 10.21147/j.issn.1000-9604.2019.04.07 shu

A ¹⁸FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer

1.
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine
2.
Department of Pathology, Peking University Cancer Hospital & Institute, Beijing 100142, China

Correspondence to: Dr. Xuejuan Wang, MD. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Nuclear Medicine, Peking University Cancer Hospital & Institute, No. 52 Fucheng Road, Haidian District, Beijing 100142, China. Email: xuejuan_wang@hotmail.com
Submitted: Sep 06, 2018
Accepted for publication: Apr 10, 2019

Figures(1) / Tables(3)

Objective: The present study investigated the prognosis value of preoperative fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in patients with local advanced gastric cancer (LAGC). Methods: In total, 144 patients [median age 63 (range: 48−80) years old] with LAGC underwent ¹⁸F-FDG PET/CT prior to any treatment. The maximum standardized uptake values (SUV_max), mean standardized uptake values (SUV_mean), metabolic tumor volume (MTV) and total lesion glycolysis (TLG) of the primary lesion were measured on PET/CT and correlated with clinicopathological features and survival. Results: Significant differences in SUV_mean, SUV_max, MTV and TLG were found according to Lauren’s classification, histologic grade and T category (P<0.05). During the 26.5-month follow-up, 51 (35.4%) patients died and 70 (48.6%) exhibited disease progression. The optimal thresholds of MTV and TLG were 15.1 cm³ and 47.3 cm³, respectively. The 3-year progression-free survival (PFS) and overall survival (OS) for patients with high TLG values were 30% and 38% compared to 38% and 47% for low TLG values, respectively (P<0.05). Univariate and multifactor analyses demonstrated that lymph node metastasis and T stage were independent prognostic factors for PFS; T stage, histologic grade and TLG were independent prognostic factors for OS (P<0.05). Molecular markers had no relationship with patient’s outcomes. Conclusions: Metabolic activity of primary gastric tumors from ¹⁸F-FDG PET/CT is a prognostic factor in patients with LAGC.
- Gastric cancer;
- ¹⁸F-FDG PET/CT;
- metabolic parameters;
- prognosis
[1]
Yang L, Zheng R, Wang N, et al. Incidence and mortality of stomach cancer in China, 2014. Chin J Cancer Res 2018;30:291-8. doi: 10.21147/j.issn.1000-9604.2018.03.01 [PubMed]

[2]
Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev 2017;8:CD004064. doi: 10.1002/14651858.CD004064.pub4 [PubMed]

[3]
Pernot S, Mitry E, Samalin E, et al. Biweekly docetaxel, fluorouracil, leucovorin, oxaliplatin (TEF) as first-line treatment for advanced gastric cancer and adenocarcinoma of the gastroesophageal junction: safety and efficacy in a multicenter cohort. Gastric Cancer 2014;17:341-7. doi: 10.1007/s10120-013-0266-6 [PubMed]

[4]
Agrawal A, Pantvaidya G, Murthy V, et al. Positron emission tomography in mucosal melanomas of head and neck: Results from a South Asian tertiary cancer care center. World J Nucl Med 2017;16:197-201. doi: 10.4103/1450-1147.207274 [PubMed]

[5]
Takashima A, Boku N, Kato K, et al. Survival prolongation after treatment failure of first-line chemotherapy in patients with advanced gastric cancer: combined analysis of the Japan Clinical Oncology group trials JCOG9205 and JCOG9912. Gastric Cancer 2014;17:522-8. doi: 10.1007/s10120-013-0309-z [PubMed]

[6]
Mochiki E, Kuwano H, Katoh H, et al. Evaluation of ¹⁸F-2-deoxy-2-fluoro-D-glucose positron emission tomography for gastric cancer. World J Surg 2004;28:247-53. doi: 10.1007/s00268-003-7191-5 [PubMed]

[7]
Park JC, Lee JH, Cheoi K, et al. Predictive value of pretreatment metabolic activity measured by fluorodeoxyglucose positron emission tomography in patients with metastatic advanced gastric cancer: the maximal SUV of the stomach is a prognostic factor. Eur J Nucl Med Mol Imaging 2012;39:1107-16. doi: 10.1007/s00259-012-2116-x [PubMed]

[8]
Kim J, Lim ST, Na CJ, et al. Pretreatment F-18 FDG PET/CT parameters to evaluate progression-free survival in gastric cancer. Nucl Med Mol Imaging 2014;48:33-40. doi: 10.1007/s13139-013-0243-3 [PubMed]

[9]
Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas: correlation with endoscopic and histopathological findings. Eur J Nucl Med Mol Imaging 2003;30:288-95. doi: 10.1007/s00259-002-1029-5 [PubMed]

[10]
Lordick F. Targeting the HGF/MET pathway in gastric cancer. Lancet Oncol 2014;15:914-6. doi: 10.1016/S1470-2045(14)70273-6 [PubMed]

[11]
Lordick F, Janjigian YY. Clinical impact of tumour biology in the management of gastroesophageal cancer. Nat Rev Clin Oncol 2016;13:348-60. doi: 10.1038/nrclinonc.2016.15 [PubMed]

[12]
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 2014;513:202-9. doi: 10.1038/nature13480 [PubMed]

[13]
Celli R, Colunga M, Patel N, et al. Metabolic signature on ¹⁸F-FDG PET/CT, HER2 status, and survival in gastric adenocarcinomas. J Nucl Med Technol 2016;44:234-8. doi: 10.2967/jnmt.116.181479 [PubMed]

[14]
Nagatsuma AK, Aizawa M, Kuwata T, et al. Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma. Gastric Cancer 2015;18:227-38. doi: 10.1007/s10120-014-0360-4 [PubMed]

[15]
Spigel DR, Ervin TJ, Ramlau RA, et al. Randomized phase II trial of Onartuzumab in combination with erlotinib in patients with advanced non-small-cell lung cancer. J Clin Oncol 2013;31:4105-14. doi: 10.1200/JCO.2012.47.4189 [PubMed]

[16]
Chung HW, Lee EJ, Cho YH, et al. High FDG uptake in PET/CT predicts worse prognosis in patients with metastatic gastric adenocarcinoma. J Cancer Res Clin Oncol 2010;136:1929-35. doi: 10.1007/s00432-010-0852-5 [PubMed]

[17]
Coupe NA, Karikios D, Chong S, et al. Metabolic information on staging FDG-PET-CT as a prognostic tool in the evaluation of 97 patients with gastric cancer. Ann Nucl Med 2014;28:128-35. doi: 10.1007/s12149-013-0791-8 [PubMed]

[18]
Chen HH, Chiu NT, Su WC, et al. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer. Radiology 2012;264:559-66. doi: 10.1148/radiol.12111148 [PubMed]

[19]
Cottereau AS, Becker S, Broussais F, et al. Prognostic value of baseline total metabolic tumor volume (TMTV0) measured on FDG-PET/CT in patients with peripheral T-cell lymphoma (PTCL). Ann Oncol 2016;27:719-24. doi: 10.1093/annonc/mdw011 [PubMed]

[20]
Abd El-Hafez YG, Moustafa HM, Khalil HF, et al. Total lesion glycolysis: a possible new prognostic parameter in oral cavity squamous cell carcinoma. Oral Oncol 2013;49:261-8. doi: 10.1016/j.oraloncology.2012.09.005 [PubMed]

[21]
Grabinska K, Pelak M, Wydmanski J, et al. Prognostic value and clinical correlations of 18-fluorodeoxyglucose metabolism quantifiers in gastric cancer. World J Gastroenterol 2015;21:5901-9. doi: 10.3748/wjg.v21.i19.5901 [PubMed]

[22]
Shiraishi N, Inomata M, Osawa N, et al. Early and late recurrence after gastrectomy for gastric carcinoma. Univariate and multivariate analyses. Cancer 2000;89:255-61. doi: 10.1002/1097-0142(20000715)89:2<255::aid-cncr8>3.0.co;2-n [PubMed]

[23]
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97. doi: 10.1016/S0140-6736(10)61121-X [PubMed]

[24]
Fuse N, Kuboki Y, Kuwata T, et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer 2016;19:183-91. doi: 10.1007/s10120-015-0471-6 [PubMed]
1. [1]
  Lei Fu, Ying Zhu, Wang Jing, Dong Guo, Li Kong, Jinming Yu. Incorporation of circulating tumor cells and whole-body metabolic tumor volume of ¹⁸F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer. Chin J Cancer Res, 2018, 30(6): 596-604. doi: 10.21147/j.issn.1000-9604.2018.06.04
2. [2]
  Shi Chen, Xijie Chen, Runcong Nie, Liying Ou Yang, Aihong Liu, Yuanfang Li, Zhiwei Zhou, Yingbo Chen, Junsheng Peng. A nomogram to predict prognosis for gastric cancer with peritoneal dissemination. Chin J Cancer Res, 2018, 30(4): 449-459. doi: 10.21147/j.issn.1000-9604.2018.04.08
3. [3]
  Xinhua Chen, Yuehong Chen, Tao Li, Luo Jun, Tian Lin, Yanfeng Hu, Huilin Huang, Hao Chen, Hao Liu, Tuanjie Li, Guoxin Li, Jiang Yu. Impact of diabetes on prognosis of gastric cancer patients performed with gastrectomy. Chin J Cancer Res, 2020, 32(5): 631-644. doi: 10.21147/j.issn.1000-9604.2020.05.08
4. [4]
  Francesco Giganti, Alessandro Ambrosi, Damiano Chiari, Elena Orsenigo, Antonio Esposito, Elena Mazza, Luca Albarello, Carlo Staudacher, Alessandro Del Maschio, Francesco De Cobelli. Apparent diffusion coefficient by diffusion-weighted magnetic resonance imaging as a sole biomarker for staging and prognosis of gastric cancer. Chin J Cancer Res, 2017, 29(2): 118-126. doi: 10.21147/j.issn.1000-9604.2017.02.04
5. [5]
  Dezső Tóth, Adrienn Bíró, Zsolt Varga, Miklós Török, Péter Árkosy. Comparison of different lymph node staging systems in prognosis of gastric cancer: a bi-institutional study from Hungary. Chin J Cancer Res, 2017, 29(4): 323-332. doi: 10.21147/j.issn.1000-9604.2017.04.05
6. [6]
  Lixin Jiang, Zengwu Yao, Yifei Zhang, Jinchen Hu, Dawei Zhao, Huiyuan Zhai, Xixun Wang, Zhenbin Zhang, Dong Wang. Comparison of lymph node number and prognosis in gastric cancer patients with perigastric lymph nodes retrieved by surgeons and pathologists. Chin J Cancer Res, 2016, 28(5): 511-518. doi: 10.21147/j.issn.1000-9604.2016.05.06
7. [7]
  Bin Ke, Han Liang. Current status of lymph node dissection in gastric cancer. Chin J Cancer Res, 2021, 33(2): 193-202. doi: 10.21147/j.issn.1000-9604.2021.02.07
8. [8]
  Wenhui Yang, Zhiyong Lai, Yuan Li, Jianbing Mu, Mudan Yang, Jun Xie, Jun Xu. Immune signature profiling identified prognostic factors for gastric cancer. Chin J Cancer Res, 2019, 31(3): 463-470. doi: 10.21147/j.issn.1000-9604.2019.03.08
9. [9]
  Jian Wang, Xi-Qiao Zhou, Jing-Ying Li, Jian-Feng Cheng, Xiao-Ning Zeng, Xiao Li, Ping Liu. Prognostic significance of ERCC1 expression in postoperative patients with gastric cancer. Chin J Cancer Res, 2014, 26(3): 323-330. doi: 10.3978/j.issn.1000-9604.2014.06.07
10. [10]
  Yoon Young Choi, Eunji Jang, Hyunki Kim, Kyoung-Mee Kim, Sung Hoon Noh, Tae Sung Sohn, Yong-Min Huh, Ji Yeong An, Jae-Ho Cheong. Single patient classifier as a prognostic biomarker in pT1N1 gastric cancer: Results from two large Korean cohorts. Chin J Cancer Res, 2021, 33(5): 583-591. doi: 10.21147/j.issn.1000-9604.2021.05.05
11. [11]
  Cheng Lu, Rakesh Shiradkar, Zaiyi Liu. Integrating pathomics with radiomics and genomics for cancer prognosis: A brief review. Chin J Cancer Res, 2021, 33(5): 563-573. doi: 10.21147/j.issn.1000-9604.2021.05.03
12. [12]
  Yilin Li, Xiaotian Zhang, Jifang Gong, Qiyue Zhang, Jing Gao, Yanshuo Cao, Daisy Dandan Wang, Peter Ping Lin, Lin Shen. Aneuploidy of chromosome 8 in circulating tumor cells correlates with prognosis in patients with advanced gastric cancer. Chin J Cancer Res, 2016, 28(6): 579-588. doi: 10.21147/j.issn.1000-9604.2016.06.04
13. [13]
  Qiyue Chen, Zhongliang Ning, Zhiyu Liu, Yanbing Zhou, Qingliang He, Yantao Tian, Hankun Hao, Wei Lin, Lixin Jiang, Gang Zhao, Ping Li, Chaohui Zheng, Changming Huang, on behalf of the Study Group for Gastric Neuroendocrine Tumors. Textbook Outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis. Chin J Cancer Res, 2021, 33(4): 433-446. doi: 10.21147/j.issn.1000-9604.2021.04.01
14. [14]
  Rui Bai, Dehao Wu, Zhong Shi, Wangxiong Hu, Juan Li, Yuanyuan Chen, Weiting Ge, Ying Yuan, Shu Zheng. Pan-cancer analyses demonstrate that ANKRD6 is associated with a poor prognosis and correlates with M2 macrophage infiltration in colon cancer. Chin J Cancer Res, 2021, 33(1): 93-102. doi: 10.21147/j.issn.1000-9604.2021.01.10
15. [15]
  Marina Alessandra Pereira, Marcus Fernando Kodama Pertille Ramos, Andre Roncon Dias, Sheila Friedrich Faraj, Cinthya dos Santos Cirqueira, Evandro Sobroza de Mello, Bruno Zilberstein, Venancio Avancini Ferreira Alves, Ulysses Ribeiro Jr.. Immunohistochemical expression of thymidylate synthase and prognosis in gastric cancer patients submitted to fluoropyrimidine-based chemotherapy. Chin J Cancer Res, 2018, 30(5): 526-536. doi: 10.21147/j.issn.1000-9604.2018.05.06
16. [16]
  Yexing Li, Zixuan Cheng, Olivier Gevaert, Lan He, Yanqi Huang, Xin Chen, Xiaomei Huang, Xiaomei Wu, Wen Zhang, Mengyi Dong, Jia Huang, Yucun Huang, Ting Xia, Changhong Liang, Zaiyi Liu. A CT-based radiomics nomogram for prediction of human epidermal growth factor receptor 2 status in patients with gastric cancer. Chin J Cancer Res, 2020, 32(1): 62-71. doi: 10.21147/j.issn.1000-9604.2020.01.08
17. [17]
  Jingming Ye, Wenjun Wang, Ling Xu, Xuening Duan, Yuanjia Cheng, Ling Xin, Hong Zhang, Shuang Zhang, Ting Li, Yinhua Liu. A retrospective prognostic evaluation analysis using the 8th edition of American Joint Committee on Cancer (AJCC) cancer staging system for luminal A breast cancer. Chin J Cancer Res, 2017, 29(4): 351-360. doi: 10.21147/j.issn.1000-9604.2017.04.08
18. [18]
  Zheng Fang, Zhiqiang Tian, Kunlun Luo, Haizhu Song, Jun Yi. Clinical significance of stanniocalcin expression in tissue and serum of gastric cancer patients. Chin J Cancer Res, 2014, 26(5): 602-610. doi: 10.3978/j.issn.1000-9604.2014.10.08
19. [19]
  Zhixue Zheng, Yiqiang Liu, Zhaode Bu, Lianhai Zhang, Ziyu Li, Hong Du, Jiafu Ji. Prognostic role of lymph node metastasis in early gastric cancer. Chin J Cancer Res, 2014, 26(2): 192-199. doi: 10.3978/j.issn.1000-9604.2014.04.06
20. [20]
  Jinou Wang, Pei Wu, Zhenning Wang, Kai Li, Baojun Huang, Pengliang Wang, Huimian Xu, Zhi Zhu. Metastatic patterns and surgical methods for lymph nodes No. 5 and No. 6 in proximal gastric cancer. Chin J Cancer Res, 2019, 31(1): 171-177. doi: 10.21147/j.issn.1000-9604.2019.01.12

PDF

Get Citation

Metrics

Abstract Views(1006)
HTML views(1122)
PDF Downloads(63)
Cited by(0)

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

A 18FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer

Metrics

通讯作者: 陈斌, bchen63@163.com

A ¹⁸FDG PET/CT-based volume parameter is a predictor of overall survival in patients with local advanced gastric cancer